The core activity of Vocoma AG is the development and provision of an innovative method for early cancer detection based on VOC biomarkers (Volatile Organic Compounds). The company aims to create a universal, reliable and accessible method for early cancer detection, enabling individuals to monitor their health and reduce the burdens associated with cancer.
AI-generated
Offering
Products & services
Industry:Medical Technology Industry
✓ Offered3
Outbound Leads by COHAGA
Looking for direct email addresses and phone numbers?
Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.
Early cancer detection using VOC biomarkers from breath, sweat, urine, stool and vaginal secretions; non-invasive sampling, analysis within 24 hours, result indicating the presence or absence of cancer.
Multi-screening platform for early cancer detection
Multi-screening platform for the simultaneous early detection of multiple cancer types, including colorectal, pancreatic, melanoma, prostate, breast, ovarian and bladder cancer.
Referral for follow-up to oncologists
After a positive test, referral to specialized and competent oncologists for further clarification and treatment.
Knowledge
No knowledge articles yet
Once Vocoma AG has claimed this profile, we'll publish editorial articles and case studies here together.